Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genta To File Complaint With FDA Over Statistical Analysis Of Genasense Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Complaint relates to 2004 analysis of Genasense progression-free survival data in melanoma, presented to the Oncologic Drugs Advisory Committee.

You may also be interested in...



Isis Fourth Quarter Strong, Antisense Rising

Cash from partners keeps company hardy as mipomersen Phase III continues.

Isis Fourth Quarter Strong, Antisense Rising

Cash from partners keeps company hardy as mipomersen Phase III continues.

Genta Expects Genasense Appeal Decision This Quarter After FDA Extends Review

Company previously had expected to hear from FDA in Q4 2007 following formal appeal of “not approvable” letter for CLL.

Related Content

Topics

UsernamePublicRestriction

Register

PS065979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel